GNRHR and diabetes insipidus: The therapeutic efficacy of such a PC approach on GPCRs was demonstrated in vivo in a hypogonadotropic hypogonadal mouse model harboring a misfolded gonadotropin-releasing hormone receptor (GnRHR) (11) and in a pilot clinical trial for the treatment of nephrogenic diabetes insipidus targeting mutant forms of vasopressin type 2 receptor (12).